Enrupatinib
As of the edition of 20 October 2026, Enrupatinib is a small molecule: in active development; acts on CSF1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2024
- Kind
- Small molecule
- Registered trials
- 2, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF1R | Macrophage colony-stimulating factor 1 receptor | P07333 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Elixiron Immunotherapeutics | Lead sponsor of trials | 2019 to now |